GPS annual expert meeting, 18-19 June 2013
Belgium
Bulgaria
General population surveys annual expert meeting, 18-19 June 2013, Lisbon
Prevalence and patterns of drug use among general population Indicator
In this section, we present the results of the annual meetings of the key indicator . Here you will find the agenda, list of participants, minutes and most of the presentations. The majority of participants have agreed to include their presentation on the public website, but a few preferred to keep them in the restricted area (you can login here).
In the annual meetings of the key indicators, experts from many countries present the latest results of their work or new data and analyses. By providing public access to these presentations, the EMCDDA aims to boost the added value of the work done on the key indicators and by the national experts.
Disclaimer: The EMCDDA is not responsible for the content of the presentations; the responsibility lies with the authors.
For further use of content of the presentations: If you wish to make use of any parts of a presentation, please contact the author directly (the e-mail and contact details are in the ‘List of participants’).
- Meeting agenda
- Meeting minutes
- List of participants
- Compilation of National Abstracts
- European Health Interview Expert List - June 2013
- Session 1
- Deborah Olszewski, EMCDDA: Overview of the meeting and update on main developments and progress in the Key Indicator
- Chloé Carpentier, EMCDDA: Developments in drug supply indicators, focusing on drug markets and drug availability
- Lydia Gisle, Belgium: Developments and progress in European Health Interview Survey (Eurostat EHIS)
- Janusz Sieroslawski, Poland: Joint action on alcohol - Work package 4 - Progress in Preparation
- Session 2
- Claudia Urbano, Portugal: Portugal General Population Survey 2012
- Darja Lavtar, Slovenia: Slovenia General Population Survey 2011/12
- Eva Januševičienė, Lithuania: Lithuania General Population Survey 2012
- Mustafa Ilhan: Turkey schools Population Survey 2012
- Session 3
- Deborah Olszewski, EMCDDA: Expert responses to question in National Abstract about response rates Panel discussion
- Ola Ekholm, Denmark: Presentation
- Daniela Piontek, Germany: Presentation
- Ståle Østhus, Norway: Presentation
- Björn Hibell, ESPAD: Presentation
- Roberto Mollica, Italy: Presentation
- Session 4
- Elena Alvarez, Spain: The utility of general population surveys for measure problematic drug use
- Nicola Singleton, United Kingdom: Are general population surveys the best tool to monitor problematic drug use?
- Danica Thanki, EMCDDA: Guidelines to monitor high risk cannabis use
- Session 5
- João Matias, EMCDDA: Summary overview of surveys results in 2013 European Drug Report and Statistical Bulletin using 2012 EMCDDA data collection
- Björn Hibell, ESPAD: Developments and progress in ESPAD
- Elena Alvarez, Spain: Prison Survey in Spain
- Session 6
- Katerina Skarupova, Czech Republic: Use of CASIC in representative surveys Panel discussion
- Karoliina Karjalainen, Finland: Presentation
- Ståle Østhus, Norway: Presentation
- Session 7
- Michael Evans-Brown, EMCDDA: European context
- Deborah Olszewski, EMCDDA: Proposed (EMQ) Module module Panel discussion
- Elena Alvarez, Spain: Presentation
- Pavla Chomynová, Czech Republic: Presentation
- Róbert Csák, Hungary: Presentation
- Session 8
- Gregor Burkhart, EMCDDA: Environmental Prevention Strategies
- Nicola Singleton, United Kingdom: Harmonised Database and polydrug use: information about progress
- Session 9
- Deborah Olszewski, EMCDDA: Results of 2013 field trial
- Björn Hibell, ESPAD: Perceived Availability of drugs in ESPAD
- João Matias, EMCDDA: Perceived availability using ESPAD
About the EMCDDA
The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) is the reference point on drugs and drug addiction information in Europe. Inaugurated in Lisbon in 1995, it is one of the EU’s decentralised agencies. Read more >>
Contact
The EMCDDA is located at:
Praça Europa 1, Cais do Sodré
1249-289 Lisbon
Portugal
Tel. (351) 211 21 02 00
